TAT congresses are medium-sized annual meetings on new molecular targets and innovative cancer therapeutics in the early phases of clinical development, supplemented by associated translational research and drug development methodology. Add to these features the high scientific standards, informal atmosphere, and active participation by the world’s leading phase 1 investigators, and you will understand why the TAT Congress series has become the prime international drug development meeting in oncology.
The program of the TAT 2017 Congress features dozens of innovative anticancer agents. Researchers will present new data on dozens of new cancer therapeutics and drug targets in various phases of (pre)clinical development, including phase 1 data that have never been presented before. Some new data from several (ongoing) phase 1 studies will only be presented on-site at the meeting and will not be released post-meeting in any form.
Prof. Lesley Seymour, Canadian Cancer Trials Group, about the TAT Congress:
“The home of phase 1 in oncology”
TAT Congresses are more than regular meetings of drug development professionals from academia and pharma and biotech industry. They are the place where the world’s leaders in early-phase development of new cancer therapeutics gather annually, establish and re-new professional and personal relationships, exchange views, discuss matters of common interest, and establish new collaborations.
“TAT is a meeting that is focusing on early drug development. It has a unique setting, because you have one single room where everything happens. The size allows for direct and friendly interactions between key opinion leaders, young investigators and industry”
(Professor Jean-Charles Soria, TAT 2017 President)